Logo

Amgen’s Lumykras (sotorasib) Receives EC’s Approval for the Treatment of Non-Small Cell Lung Cancer

Share this

Amgen’s Lumykras (sotorasib) Receives EC’s Approval for the Treatment of Non-Small Cell Lung Cancer

Shots:

  • The EC has granted conditional marketing authorization for Lumykras (KRASG12C inhibitor) in adults with advanced NSCLC with KRAS G12C mutation who have progressed after one prior line of systemic therapy
  • The approval is based on the P-II (CodeBreaK 100) trial to evaluate Lumykra (960mg, PO, qd) in 126 patients with advanced NSCLC which showed an ORR (37.1%), m-DoR of 11.1mos. along with a  favorable benefit-risk profile of Lumykras
  • Lumykra is the 1st targeted therapy to be approved in the EU & is also being evaluated in multiple P-Ib (CodeBreaK 101) studies as monothx. and in combination therapy for the treatment of multiple advanced solid tumors

Ref: PR Newswire | Image: Fierce Pharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions